Amgen (AMGN-NASDAQ) posted EPS of $0.90, but $0.71 on GAAP EPS. Revenues were $3.73 Billion versus $3.7 Billion estimates. Revenues are projected for $15.4 to $16 Billion for 2007 and adjusted EPS put for 2007 at $4.30 to $4.50. Estimates for the quarter were $0.94 to $0.95 depending on your consensus, but 2007 estimates are $4.43.
The stock closed down 0.4% at $74.85 and is down almost 2% around $73.50 in the initial reaction. At the mid-point this is only a 17 P/E for 2007, so investors aren’t willing to pay up for Amgen’s earnings based on Congressional scares and potential patent issues in 2008 and beyond. The valuation isn’t the issue here, because this ons has been cheaper than many Big Pharma stocks for a while. Its market cap is $87 Billion.
Amgen is no longer treated like a biotech, it’s treated like a plain Jane drug stock. That might not be fair, but the market sets the rules.
Jon C. Ogg
January 25, 2007
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
